Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ENO Lime · 1 trial · 3 indications
The severity of symptoms of Ajeerna vyadhi will be recorded using VAS scoring. Participants will record a score with a mark at one point along the length of a 100-millimeter (mm) line, where the lowest score 0-mm indicates 'no discomfort' and highest score 100-mm indicates 'worst possible discomfort'. Higher the score, more severe will be the symptoms. Change from baseline will be calculated by subtracting baseline value from the value at 15-minutes.
| Arm | Type | Description |
|---|---|---|
| ENO Lime | EXPERIMENTAL | Participants will be instructed to take 1 sachet of ENO Lime powder with approximately 150 milliliters (ml) of normal water as a single dose. Participants will be advised to repeat the dose after 2-hours, if necessary (Maximum 2 sachet per 24-hours). Participants will be followed up for 24-hours. |
| Name | Type | Description |
|---|---|---|
| ENO Lime | DRUG | A fruit salt (sachet of 5-gram powder) with lime flavor containing Svarjiksara (Shudh) 2220 milligram (mg) and Nimbu Rasa (Citrus limon, Fruit Juice Powder) 150 mg |
Inclusion Criteria: * Male and female participants with age 18-60 years (both inclusive). * Participants newly experiencing symptom/s of Ajeerna vyadhi for not more than 10 days. * Participants with at least one symptom of Ajeerna vyadhi (according to Charak Samhita and Madhav Nidan) that is acidit...
ENO Lime is used for indigestion and acid indigestion, including associated nausea. It is being studied in a clinical trial for Ajeerna Vyadhi, which covers acidity, acid indigestion, indigestion, and associated nausea. The drug is in Phase 3 clinical development.
ENO Lime is developed by Haleon plc, a company listed on the stock exchange under the ticker HLN. The drug is currently in Phase 3 clinical development for the treatment of indigestion and acid indigestion.
ENO Lime is in Phase 3 clinical development. It is an investigational drug being studied for indigestion and acid indigestion, including associated nausea. The drug has completed one Phase 3 clinical trial and is not yet approved by regulatory authorities.
ENO Lime has one completed Phase 3 clinical trial, identified as NCT07140341. This study assessed the effectiveness of ENO Lime in participants with Ajeerna Vyadhi, which includes acidity, acid indigestion, indigestion, and associated nausea. The trial was conducted in India with 40 participants.
Yes, ENO Lime is a small molecule drug. It is being developed by Haleon plc for the treatment of indigestion and acid indigestion. The drug is currently in Phase 3 clinical development and is classified under the gastrointestinal therapeutic area.